Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 14 peer-reviewed journal articles Updated
Oncology

Special Considerations for Treating LFS Cancers

At a Glance

Cancer treatment for Li-Fraumeni Syndrome (LFS) prioritizes avoiding radiation therapy. LFS cells cannot easily repair DNA damage, raising the risk of secondary tumors. Instead, doctors often recommend extensive surgeries and targeted therapies guided by precision molecular profiling.

Treating cancer when you have Li-Fraumeni Syndrome (LFS) requires a specialized strategy. Because your cells have a weakened ability to repair DNA damage, some “standard” treatments can actually increase the risk of developing a second, new cancer later on [1][2].

The Paramount Rule: Avoiding Radiation

In most cancer cases, radiation therapy is a common tool. However, in LFS, ionizing radiation is generally avoided whenever surgically possible [1][3].

  • The Risk: Radiation works by damaging the DNA of cancer cells. Because LFS patients lack a fully functional TP53 “guardian” gene, their healthy cells cannot easily repair this damage. This significantly increases the risk of radiation-induced secondary (RIS) tumors—new cancers that develop in the area where radiation was delivered [4][1].
  • The Decision: In some life-threatening situations, a medical team may decide the immediate benefit of radiation outweighs the long-term risk. This decision should always be made by a multidisciplinary team familiar with LFS [3].

Surgical Nuances

Because of the radiation risk, surgical choices are often more extensive in LFS:

  • Breast Cancer: For women with LFS, a bilateral mastectomy (removing both breasts) is often preferred over a lumpectomy [5][6]. A lumpectomy usually requires follow-up radiation. A mastectomy often eliminates the need for radiation and prevents future cancers in the remaining breast tissue [5][3].
  • Aggressive Resection: For other tumors like sarcomas, surgeons often aim for very aggressive resections with wide “margins” to ensure no cancer cells are left behind, reducing the need for additional treatments [7].

The Role of Precision Oncology

The most exciting advancement in LFS treatment is precision oncology—tailoring treatment to the specific genetic “blueprint” of the tumor [8].

  • Molecular Profiling: Doctors can sequence the DNA of the tumor itself to find specific “drivers” or mutations that are helping the cancer grow [8][9].
  • Targeted Therapies: Once these drivers are found, doctors may use drugs that target those specific weaknesses [8][10].
  • Immunotherapy: Immunotherapies, like CAR T-cell therapy, are standard for certain blood cancers (like specific leukemias) and offer options without the widespread DNA damage of traditional treatments [11]. While not yet standard for solid tumors (like brain tumors), immunotherapies and checkpoint inhibitors are being actively explored in clinical trials for solid tumors in LFS patients [12][11].

Multidisciplinary Care

Because LFS is complex, you should ideally be treated by a team that includes surgeons, oncologists, geneticists, and a molecular tumor board [8]. For many, this may also include exploring clinical trials for new preventive or targeted drugs [13][14]. You can read more about tracking symptoms and early detection on The Toronto Protocol: Your Roadmap for Surveillance.

Common questions in this guide

Why do doctors try to avoid using radiation therapy for LFS patients?
Radiation damages DNA, which healthy cells normally repair. Because people with LFS have a mutated TP53 gene, their cells cannot properly fix this damage. This significantly increases the risk of developing a new, secondary cancer in the area that received radiation.
What is the recommended surgery for breast cancer if I have LFS?
Doctors often recommend a bilateral mastectomy, which is the removal of both breasts, instead of a lumpectomy. A lumpectomy usually requires follow-up radiation, whereas a mastectomy often eliminates the need for radiation and prevents future cancers in the remaining breast tissue.
How does precision medicine help treat LFS cancers?
Precision medicine involves testing the tumor's DNA to find the specific genetic mutations driving its growth. Once identified, doctors can use targeted drugs or immunotherapies that attack those specific cancer cells without causing widespread DNA damage.
What is a molecular tumor board and why do I need one?
A molecular tumor board is a group of experts who review your tumor's specific genetic profile. They work together to find specialized, targeted treatments or clinical trials that might be more effective and safer for your specific cancer type.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Are there surgical or systemic treatment options that can help us avoid the use of radiation therapy?
  2. 2.Does this hospital have a molecular tumor board that can review my case to look for targeted therapy options?
  3. 3.For breast cancer treatment, what are the pros and cons of a bilateral mastectomy compared to a lumpectomy followed by radiation in the context of LFS?
  4. 4.Are there any clinical trials for immunotherapy or targeted drugs that might be appropriate for this specific type of tumor?
  5. 5.How will we monitor for secondary cancers during and after this treatment?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (14)
  1. 1

    Lessons Learned in Practice with Li-Fraumeni Syndrome: LFS-Related Breast Cancer Treatment Strategy and Establishment of a Surveillance System.

    Sasaki R, Horimoto Y, Saeki H, et al.

    Juntendo Iji zasshi = Juntendo medical journal 2022; (68(4)):405-412 doi:10.14789/jmj.JMJ22-0012-CR.

    PMID: 39021431
  2. 2

    Modeling of osteosarcoma with induced pluripotent stem cells.

    Pang LK, Pena M, Zhao R, Lee DF

    Stem cell research 2020; (49()):102006 doi:10.1016/j.scr.2020.102006.

    PMID: 33022533
  3. 3

    Frequency of radiation-induced malignancies post-adjuvant radiotherapy for breast cancer in patients with Li-Fraumeni syndrome.

    Le AN, Harton J, Desai H, et al.

    Breast cancer research and treatment 2020; (181(1)):181-188 doi:10.1007/s10549-020-05612-7.

    PMID: 32246378
  4. 4

    Radiation-induced sarcoma after glioma resection in patients with Li-Fraumeni syndrome: illustrative cases.

    Kondapavulur S, Young JS, Berger MS

    Journal of neurosurgery. Case lessons 2025; (10(23)).

    PMID: 41569911
  5. 5

    Uptake and timing of bilateral and contralateral risk-reducing mastectomy in women with Li-Fraumeni syndrome.

    Siegel A, Bremer RC, Klein WMP, et al.

    Breast cancer research and treatment 2022; (191(1)):159-167 doi:10.1007/s10549-021-06410-5.

    PMID: 34652547
  6. 6

    Optimizing shared decision-making for risk-reducing mastectomy in women with Li-Fraumeni syndrome using patient-reported outcome measures.

    Polidorio N, Sandoval RL, Bioni P, et al.

    Scientific reports 2025; (15(1)):19449 doi:10.1038/s41598-025-89068-z.

    PMID: 40461682
  7. 7

    Management of orbital rhabdomyosarcoma in a child with Li-Fraumeni syndrome.

    Jivraj I, Somers GR, Belliveau MJ, et al.

    Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus 2019; (23(3)):182-185 doi:10.1016/j.jaapos.2019.01.013.

    PMID: 30974170
  8. 8

    Exploiting somatic oncogenic driver alterations in a patient with Li-Fraumeni syndrome- paving the path towards precision medicine: a case report.

    Seeling C, Dahlum S, Marienfeld R, et al.

    Journal of cancer research and clinical oncology 2025; (151(1)):37 doi:10.1007/s00432-024-06077-7.

    PMID: 39820556
  9. 9

    A deep analysis using panel-based next-generation sequencing in an Ecuadorian pediatric patient with anaplastic astrocytoma: a case report.

    García-Cárdenas JM, Zambrano AK, Guevara-Ramírez P, et al.

    Journal of medical case reports 2020; (14(1)):136 doi:10.1186/s13256-020-02451-4.

    PMID: 32867815
  10. 10

    Current insights and future directions of Li-Fraumeni syndrome.

    Hosseini MS

    Discover oncology 2024; (15(1)):561 doi:10.1007/s12672-024-01435-w.

    PMID: 39404911
  11. 11

    CAR T-cell therapy for a relapsed/refractory acute B-cell lymphoblastic lymphoma patient in the context of Li-Fraumeni syndrome.

    Chen L, Xu B, Long X, et al.

    Journal for immunotherapy of cancer 2020; (8(1)) doi:10.1136/jitc-2019-000364.

    PMID: 32345625
  12. 12

    Long-term survival in a patient with Li-Fraumeni syndrome-associated giant cell glioblastoma treated with nivolumab: illustrative case.

    Mitchell M, Restrepo-Orozco A, Verhey LH, Vitaz T

    Journal of neurosurgery. Case lessons 2024; (8(22)).

    PMID: 39586078
  13. 13

    Pilot Study Assessing Tolerability and Metabolic Effects of Metformin in Patients With Li-Fraumeni Syndrome.

    Walcott FL, Wang PY, Bryla CM, et al.

    JNCI cancer spectrum 2020; (4(6)):pkaa063 doi:10.1093/jncics/pkaa063.

    PMID: 33490865
  14. 14

    Li-Fraumeni Syndrome : Current Strategies and Future Perspectives.

    Lee JW

    Journal of Korean Neurosurgical Society 2025; (68(3)):305-310 doi:10.3340/jkns.2025.0050.

    PMID: 40289692

This page discusses cancer treatment strategies for Li-Fraumeni Syndrome for educational purposes only. Always consult your oncology team and a geneticist to make the best treatment decisions for your specific case.

Get notified when new evidence is published on Li-Fraumeni syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.